US20090162428A1 - Immediate disintegration polyvalent polymeric matrix for modified release solid oral preparations and method of preparation thereof - Google Patents

Immediate disintegration polyvalent polymeric matrix for modified release solid oral preparations and method of preparation thereof Download PDF

Info

Publication number
US20090162428A1
US20090162428A1 US12/317,427 US31742708A US2009162428A1 US 20090162428 A1 US20090162428 A1 US 20090162428A1 US 31742708 A US31742708 A US 31742708A US 2009162428 A1 US2009162428 A1 US 2009162428A1
Authority
US
United States
Prior art keywords
polymeric matrix
active substance
matrix
matrix according
excipients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/317,427
Inventor
Gino Pasotti
Andrea Spalla
Ezio De Zanet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International Products and Services IPS Srl
Original Assignee
International Products and Services IPS Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International Products and Services IPS Srl filed Critical International Products and Services IPS Srl
Assigned to I.P.S. INTERNATIONAL PRODUCTS & SERVICES S.R.L. reassignment I.P.S. INTERNATIONAL PRODUCTS & SERVICES S.R.L. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PASOTTI, GINO, DE ZANET, EZIO, SPALLA, ANDREA
Publication of US20090162428A1 publication Critical patent/US20090162428A1/en
Priority to US13/729,837 priority Critical patent/US9333170B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/70—Fixation, conservation, or encapsulation of flavouring agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to an immediate disintegration polymeric polyvalent matrix, suitable for the oral administration of modified release solid products and the related method of its production.
  • the traditional systems to obtain forms of oral administration of medicaments or food supplements with modified release comprise the preparation of tablets, capsules, granulates that once swallowed release the active substance in the gastrointestinal tract according to predeterminated modes.
  • This release is obtained by application of the active substance on an inert core and then covering the whole with one or more layers of outer membranes comprising substances adapted to provide the desired modified release, that can be a controlled, retarded, extended release according to the substances used for the cover membranes.
  • microgranules, pellets or minipellets according to their size are obtained.
  • the present invention solves brilliantly and surprisingly the above mentioned problems, with the revolutionary provision of an immediate disintegration polyvalent matrix comprising an agglomerate formed by particles of active substance, directly covered by one or more layers of polymeric membranes having such characteristics as to keep the active substance fully isolated from the outer environment and to adjust the release according to predeterminated modes, thus totally removing the need of an inert support core.
  • such a matrix can attain an active substance titer much higher than the conventional microgranules, pellets and minipellets, thus allowing to make final administration forms with much higher dosages and better possibility to add other active substances, avoiding to make recourse to divide the total dosage into several unitary doses.
  • This matrix has a polyvalent function as well, because it allows to make different administration forms of solid oral products, such as high dosage tablets, even fractionable, without altering the modified release characteristics (as it happens with the traditional retard tablets), thus allowing to obtain an optimal flexibility of the unitary dosages to be administered.
  • These tablets can also be crumbled, in case of swallowing difficulties, in a spoon or directly in the oral cavity and then swallowed with a minimal amount of water or other liquids.
  • the same matrix of the present invention when used in its simplest form of agglomerate of particles of active substance directly covered with one or more layers of polymeric membrane, allows to make other final dosage forms such as hard gelatine capsules, single dose sachets, oral soluble sachets, bottles with metering stopper.
  • All the above mentioned forms of dosage cause the active substance to reach promptly after the administration the gastrointestinal tract starting the modified release, at the stomach and/or intestine level according to the properties of the used membrane and in view of the particular characteristics of fine and flowable particle size, the active substance spreads in a quick and uniform way on the whole surface of the gastrointestinal tract.
  • inventive matrix The positive characteristics and advantages of the inventive matrix are numerous and important for the various administration forms that can be formulated and the following may be mentioned without being limited thereto.
  • the matrix always shows the same predeterminated characteristics of progressive, constant and gradual release by diffusion with time.
  • the matrix always covers a broad surface of the gastrointestinal tract due to the immediate tablet disintegration, with a minimal concentration of the active substance around each particle, with the above mentioned advantages in respect of the traditional tablets, even superior to pellets and minipellets, in view of the finer particle size.
  • the behavior of the matrix is not affected by the tabletting operation in view of the very reduced particle size and the greater pressure resistance in comparison with the traditional pellets and minipellets as well.
  • the tablet formulation of the matrix does not cause phenomena of surface polymerisation, that are very frequent with some low melting active ingredients such as thioptic or alpha lipoic acid, a classic problem found with traditional tablets, with consequent release interruption and modification of the retard effect.
  • the matrix components Independently from the processed active substance, the matrix components have flavor masking properties, thus allowing the formulation of administration forms having a direct contact with taste buds.
  • Flavoring or sweetening ingredients may also be added to the matrix components, so that ingestion of these final forms such as fractionable or crumbling tablets, extemporaneous suspensions, single dose sachets and so forth, is also palatable, with clear advantages especially in case of pediatric use.
  • the components of the matrix have such a specific weight, in view of their minimal size and absence of weighing down inert supports, as to allow a uniform suspension in the liquid used for the extemporaneous suspensions or single dose sachets, for the time required for its ingestion after a minimal shaking of the container, eliminating the product foot remaining in the emptied container, as it frequently happens when administering minipellets.
  • the active ingredient is covered using a 30% solution of 300 g shellac in ethanol and 300 g talc.
  • the covering operation may be effected continuously or in various stages until the required release rate is attained.
  • the product is sieved with a 790 ⁇ m mesh and dusted with a 425 ⁇ m mesh.
  • the product is left drying in the pan for 3 hours at room temperature.
  • the finished product has a final titer of 880 mg/g and the release data obtained using the methodology “Dissolution test for solid oral forms” described in the European Pharmacopoeia are the following:
  • the bulk density results to be between 0.3-0.5, so that the product obtained as above stated, can be blended with excipients like cellulose, maize starch, powdered flavors and others, to make a compression obtaining a matrix where the active substance is distributed homogeneously, according to the criteria set by the European Pharmacopoeia.

Abstract

An immediate disintegrating polymeric matrix for oral administration with modified release is disclosed, obtained without using inert supports such as sugar spheres, comprising particles of active substance directly covered with a release regulating membrane. Use of such a matrix to prepare various administration forms for oral use as well as the method of its preparation are also disclosed.

Description

    FIELD OF THE INVENTION
  • The present invention relates to an immediate disintegration polymeric polyvalent matrix, suitable for the oral administration of modified release solid products and the related method of its production.
    • BACKGROUND OF THE INVENTION
  • The traditional systems to obtain forms of oral administration of medicaments or food supplements with modified release comprise the preparation of tablets, capsules, granulates that once swallowed release the active substance in the gastrointestinal tract according to predeterminated modes.
  • This release is obtained by application of the active substance on an inert core and then covering the whole with one or more layers of outer membranes comprising substances adapted to provide the desired modified release, that can be a controlled, retarded, extended release according to the substances used for the cover membranes.
  • In this way the so-called microgranules, pellets or minipellets according to their size are obtained.
  • However these systems inevitably have some drawbacks, mainly due to the necessity of adding inert ingredients (support cores available on the market, known as sugar spheres) to the active substance. Therefore for the administration of the required dosage, the volume of the final administration form must be increased, with relevant swallowing difficulties, more particularly for high dosages, or the total dosage must be divided into several unitary doses.
    • SUMMARY OF THE INVENTION
  • The present invention solves brilliantly and surprisingly the above mentioned problems, with the revolutionary provision of an immediate disintegration polyvalent matrix comprising an agglomerate formed by particles of active substance, directly covered by one or more layers of polymeric membranes having such characteristics as to keep the active substance fully isolated from the outer environment and to adjust the release according to predeterminated modes, thus totally removing the need of an inert support core.
  • In this way such a matrix can attain an active substance titer much higher than the conventional microgranules, pellets and minipellets, thus allowing to make final administration forms with much higher dosages and better possibility to add other active substances, avoiding to make recourse to divide the total dosage into several unitary doses.
  • This matrix has a polyvalent function as well, because it allows to make different administration forms of solid oral products, such as high dosage tablets, even fractionable, without altering the modified release characteristics (as it happens with the traditional retard tablets), thus allowing to obtain an optimal flexibility of the unitary dosages to be administered.
  • These tablets can also be crumbled, in case of swallowing difficulties, in a spoon or directly in the oral cavity and then swallowed with a minimal amount of water or other liquids.
  • Moreover the matrix in the formulation of disintegrating tablets, to be considered as a mere container or proportioner of the modified release active substance and not as a traditional tablet, allows also to obtain extemporaneous suspensions with a great dosage variety, by disintegrating for instance half tablet=200 mg; one tablet=400 mg; one and a half tablet=600 mg and so forth, in any suitable liquid, and then swallowing the active substance, whose modified release characteristics were not affected, in the form of a homogeneous suspension, very suitable for geriatric and pediatric use.
  • Moreover the same matrix of the present invention, when used in its simplest form of agglomerate of particles of active substance directly covered with one or more layers of polymeric membrane, allows to make other final dosage forms such as hard gelatine capsules, single dose sachets, oral soluble sachets, bottles with metering stopper.
  • All the above mentioned forms of dosage cause the active substance to reach promptly after the administration the gastrointestinal tract starting the modified release, at the stomach and/or intestine level according to the properties of the used membrane and in view of the particular characteristics of fine and flowable particle size, the active substance spreads in a quick and uniform way on the whole surface of the gastrointestinal tract.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The positive characteristics and advantages of the inventive matrix are numerous and important for the various administration forms that can be formulated and the following may be mentioned without being limited thereto.
  • Whatever the final implemented form may be, such as tablets, extemporaneous preparations, oral soluble sachets and so on, the matrix always shows the same predeterminated characteristics of progressive, constant and gradual release by diffusion with time.
  • Even when formulated as a tablet, the matrix always covers a broad surface of the gastrointestinal tract due to the immediate tablet disintegration, with a minimal concentration of the active substance around each particle, with the above mentioned advantages in respect of the traditional tablets, even superior to pellets and minipellets, in view of the finer particle size.
  • The behavior of the matrix is not affected by the tabletting operation in view of the very reduced particle size and the greater pressure resistance in comparison with the traditional pellets and minipellets as well.
  • The tablet formulation of the matrix does not cause phenomena of surface polymerisation, that are very frequent with some low melting active ingredients such as thioptic or alpha lipoic acid, a classic problem found with traditional tablets, with consequent release interruption and modification of the retard effect.
  • Independently from the processed active substance, the matrix components have flavor masking properties, thus allowing the formulation of administration forms having a direct contact with taste buds.
  • Flavoring or sweetening ingredients may also be added to the matrix components, so that ingestion of these final forms such as fractionable or crumbling tablets, extemporaneous suspensions, single dose sachets and so forth, is also palatable, with clear advantages especially in case of pediatric use.
  • The components of the matrix have such a specific weight, in view of their minimal size and absence of weighing down inert supports, as to allow a uniform suspension in the liquid used for the extemporaneous suspensions or single dose sachets, for the time required for its ingestion after a minimal shaking of the container, eliminating the product foot remaining in the emptied container, as it frequently happens when administering minipellets.
    • EXAMPLE
  • As a merely illustrative and non limiting example of the general application of the present invention, the method of preparation of a polymeric polyvalent matrix of thioptic acid is given hereinafter, a food supplement which is well adapted to be an illustrative example.
  • To obtain a matrix with the mentioned characteristics it is necessary to have at disposal a starting material with a particle size between 200 and 700 μm.
  • The method of production to carry out direct application on the active substance of one or more layers of polymeric membrane regulating the release is as follows:
  • 3.0 kg of a starting material having the above stated particle size is charged in a 10 l revolving pan.
  • While the pan is rotating, the active ingredient is covered using a 30% solution of 300 g shellac in ethanol and 300 g talc.
  • The covering operation may be effected continuously or in various stages until the required release rate is attained.
  • At the end of said operation the product is sieved with a 790 μm mesh and dusted with a 425 μm mesh.
  • The product is left drying in the pan for 3 hours at room temperature.
  • The finished product has a final titer of 880 mg/g and the release data obtained using the methodology “Dissolution test for solid oral forms” described in the European Pharmacopoeia are the following:
  • after 1 hour: 18.9%; after 2 hours: 36.0%; after 4 hours: 62.3%; after 8 hours: 86.9%.
  • The bulk density results to be between 0.3-0.5, so that the product obtained as above stated, can be blended with excipients like cellulose, maize starch, powdered flavors and others, to make a compression obtaining a matrix where the active substance is distributed homogeneously, according to the criteria set by the European Pharmacopoeia.
  • Matrices produced using a mixture of excipients by direct compression, analysed according to the above described methodology, did not show release variations, so that the method of preparation of the matrices is such as not to cause degradation of lipoic acid and the whole production process keeps the chemical integrity of this active substance.
  • Finally it is to be pointed out that many variations, additions and/or substitutions may be resorted to the polymeric matrix, more particularly concerning the nature of polymers used as a function of the kind of modified release to be obtained and its method of production, without departing however from its characteristics nor falling out of its scope of protection, as defined in the appended claims.

Claims (20)

1. A prompt disintegration polymeric matrix for oral administration with modified release, comprising particles of active substance directly covered with a release regulating membrane where use of inert supports is eliminated.
2. The polymeric matrix of claim 1, wherein the cover membrane comprises a solution of shellac in ethanol and talc.
3. The polymeric matrix of claim 1, wherein the matrix blended with excipients is compressed directly to obtain tablets with immediate disintegration.
4. The polymeric matrix according to claim 1, wherein the matrix is blended with flavoring and other excipients masking the taste of the active substance, for a better compliance of users.
5. The polymeric matrix according to claim 1, wherein the active substance is a pharmaceutical substance.
6. The polymeric matrix according to claim 5, wherein the matrix is a medicament comprising one or more active substances.
7. The polymeric matrix according to claim 1, wherein the active substance is a food supplement.
8. The polymeric matrix according to claim 7, wherein the food supplement is thioptic or alpha-lipoic acid.
9. Use of the matrix according to claim 1, to prepare a homogeneous and uniform extemporaneous suspension in a reduced amount of liquid.
10. Use of the matrix according claim 1, to prepare hard gelatine capsules.
11. Use of the matrix according to claim 1, to prepare single dose oral soluble sachets.
12. A method of preparing a disintegrating polymeric matrix for oral use with modified release according to claim 1, comprising the steps of:
charging in a rotary pan a starting material comprising an active substance with particle size between 200 and 700 μm;
rotating the pan directly covering the particles of active substance in one or more stages with one or more layers of release regulating polymeric membrane;
at the end of the covering step, sieving the product with a mesh of 790 μm and dusting with a mesh of 425 μm; and
drying the product in the pan at room temperature.
13. The method according to claim 12, wherein the polymeric matrix is blended with excipients to make disintegrating tablets and single dose oral soluble sachets.
14. The method according to claim, wherein the polymeric matrix is blended with flavoring and other excipients for masking the taste of the active substance.
15. The method according to claim 12, wherein two or more active substances are mixed for a combination therapy or food integration.
16. The polymeric matrix according to claim 2, wherein the matrix is blended with flavoring and other excipients masking the taste of the active substance, for a better compliance of users.
17. The polymeric matrix according to claim 3, wherein the matrix is blended with flavoring and other excipients masking the taste of the active substance, for a better compliance of users.
18. The polymeric matrix according to claim 17, wherein the active substance is a pharmaceutical substance.
19. The polymeric matrix according to claim 16, wherein the active substance is a pharmaceutical substance.
20. The polymeric matrix according to claim 15, wherein the active substance is a pharmaceutical substance.
US12/317,427 2007-12-24 2008-12-23 Immediate disintegration polyvalent polymeric matrix for modified release solid oral preparations and method of preparation thereof Abandoned US20090162428A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/729,837 US9333170B2 (en) 2007-12-24 2012-12-28 Polyvalent polymeric matrix for modified release solid oral preparations and method of preparation thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2007A002427 2007-12-24
IT002427A ITMI20072427A1 (en) 2007-12-24 2007-12-24 POLYMAL POLYMERIC MATRICES WITH IMMEDIATE DEGRADATION FOR SOLID PRODUCTS FOR ORAL USE WITH MODIFIED RELEASE AND METHOD FOR ITS PREPARATION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/729,837 Continuation-In-Part US9333170B2 (en) 2007-12-24 2012-12-28 Polyvalent polymeric matrix for modified release solid oral preparations and method of preparation thereof

Publications (1)

Publication Number Publication Date
US20090162428A1 true US20090162428A1 (en) 2009-06-25

Family

ID=40315655

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/317,427 Abandoned US20090162428A1 (en) 2007-12-24 2008-12-23 Immediate disintegration polyvalent polymeric matrix for modified release solid oral preparations and method of preparation thereof
US13/729,837 Active US9333170B2 (en) 2007-12-24 2012-12-28 Polyvalent polymeric matrix for modified release solid oral preparations and method of preparation thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/729,837 Active US9333170B2 (en) 2007-12-24 2012-12-28 Polyvalent polymeric matrix for modified release solid oral preparations and method of preparation thereof

Country Status (3)

Country Link
US (2) US20090162428A1 (en)
EP (1) EP2074991A1 (en)
IT (1) ITMI20072427A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130115282A1 (en) * 2007-12-24 2013-05-09 I. P.S. International Products & Services S.r.I. Polyvalent polymeric matrix for modified release solid oral preparations and method of preparation thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3865124A1 (en) 2012-12-28 2021-08-18 I.P.S. International Products & Services S.r.l. Polyvalent polymeric matrix for modified release solid oral preparations and method of preparation thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3081233A (en) * 1960-08-08 1963-03-12 Upjohn Co Enteric-coated pilules
US5376382A (en) * 1992-03-11 1994-12-27 Asta Medica Aktiengesellschaft Tablets, granulates and pellets with a high active substance content for highly concentrated, solid dosage forms of thioctic acid
US6120491A (en) * 1997-11-07 2000-09-19 The State University Rutgers Biodegradable, anionic polymers derived from the amino acid L-tyrosine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060024367A1 (en) * 1998-05-28 2006-02-02 Byrd Edward A Controlled release alpha lipoic acid formulation with an inositol compound
WO2006052968A2 (en) * 2004-11-05 2006-05-18 King Pharmaceuticals Research & Development, Inc. Stabilized ramipril compositions and methods of making
ITMI20061024A1 (en) 2006-05-25 2007-11-26 Eurand Pharmaceuticals Ltd PELLETS BASED ON LIPOIC ACID
ITMI20072427A1 (en) * 2007-12-24 2009-06-25 I P S Internat Products & Ser POLYMAL POLYMERIC MATRICES WITH IMMEDIATE DEGRADATION FOR SOLID PRODUCTS FOR ORAL USE WITH MODIFIED RELEASE AND METHOD FOR ITS PREPARATION

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3081233A (en) * 1960-08-08 1963-03-12 Upjohn Co Enteric-coated pilules
US5376382A (en) * 1992-03-11 1994-12-27 Asta Medica Aktiengesellschaft Tablets, granulates and pellets with a high active substance content for highly concentrated, solid dosage forms of thioctic acid
US6120491A (en) * 1997-11-07 2000-09-19 The State University Rutgers Biodegradable, anionic polymers derived from the amino acid L-tyrosine

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130115282A1 (en) * 2007-12-24 2013-05-09 I. P.S. International Products & Services S.r.I. Polyvalent polymeric matrix for modified release solid oral preparations and method of preparation thereof
US9333170B2 (en) * 2007-12-24 2016-05-10 I.P.S. International Products & Services S.R.L. Polyvalent polymeric matrix for modified release solid oral preparations and method of preparation thereof

Also Published As

Publication number Publication date
EP2074991A1 (en) 2009-07-01
ITMI20072427A1 (en) 2009-06-25
US9333170B2 (en) 2016-05-10
US20130115282A1 (en) 2013-05-09

Similar Documents

Publication Publication Date Title
GB2101484A (en) Oral dipyridamole compositions
WO2007074856A1 (en) Method of producing solid preparation disintegrating in the oral cavity
JPH0122245B2 (en)
JPH01503070A (en) Drug sustained release matrices and methods
SA518391206B1 (en) Modified Release Orally Administered Amino Acid Formulations
TWI695722B (en) Solid preparation outer layer composition and easy-to-take solid preparation containing the outer layer composition
KR20000076475A (en) Process for the preparation of pellets with a content of up to 90wt% of a pharmaceutical active ingredient
JP2599189B2 (en) Chewable drug tablets containing taste-masking agents
JP4783573B2 (en) Warfarin potassium-containing pharmaceutical composition and method for producing the same
JP6998210B2 (en) Particle composition for easy-to-take solid preparation and easy-to-take solid preparation containing the particle composition
CN113413388A (en) Sildenafil citrate-containing pharmaceutical composition, preparation method and application thereof
WO1991001734A1 (en) Prednisone microencapsulated granules
CN104352441A (en) DMF (dimethyl fumarate) enteric-coated micropellet and preparation method thereof
UA120715C2 (en) Enteric-coated pellets containing a proton pump inhibitor
JP6084355B2 (en) Ambroxol-containing preparation particles
JPH06219939A (en) Rotating tablet-forming and taste-covering coating processing for preparing chewable medical tablet
US20090162428A1 (en) Immediate disintegration polyvalent polymeric matrix for modified release solid oral preparations and method of preparation thereof
CN114302712B (en) Acipimox multi-unit sustained-release pellet tablet and preparation method thereof
JPH03145418A (en) Sustained release preparation of basic drug hydrochloride
CN108014085A (en) A kind of preparation method and applications of sabril solid composite
WO2008111871A1 (en) Peroral memantine-based medicinal preparation and a method for the production thereof
JP4400941B2 (en) Kampo-containing tablets, Kampo-filled capsules, herbal medicine-containing tablets, herbal medicine-filled capsules, manufacturing method of Kampo-containing tablets, herbal medicine-containing capsules, herbal medicine-containing tablets, and herbal medicine-filled capsules
US20070077294A1 (en) Capsules comprising topiramate
JP5903250B2 (en) Sustained release composition
JPH11343231A (en) Granular preparation collapsible in oral cavity

Legal Events

Date Code Title Description
AS Assignment

Owner name: I.P.S. INTERNATIONAL PRODUCTS & SERVICES S.R.L.,IT

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PASOTTI, GINO;SPALLA, ANDREA;DE ZANET, EZIO;SIGNING DATES FROM 20081204 TO 20081205;REEL/FRAME:022072/0680

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION